Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.
Rivero R, Esteva MI, Huang E, Colmegna L, Altcheh J, Grossmann U, Ruiz AM; CHICO and CHICO SECURE Study Groups. Rivero R, et al. Among authors: altcheh j. PLoS Negl Trop Dis. 2023 Jun 23;17(6):e0011440. doi: 10.1371/journal.pntd.0011440. eCollection 2023 Jun. PLoS Negl Trop Dis. 2023. PMID: 37352322 Free PMC article. Clinical Trial.
Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
Altcheh J, Castro L, Dib JC, Grossmann U, Huang E, Moscatelli G, Pinto Rocha JJ, Ramírez TE; CHICO Study Group. Altcheh J, et al. PLoS Negl Trop Dis. 2021 Jan 7;15(1):e0008912. doi: 10.1371/journal.pntd.0008912. eCollection 2021 Jan. PLoS Negl Trop Dis. 2021. PMID: 33412557 Free PMC article. Clinical Trial.
Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study.
González NL, Moscatelli G, Moroni S, Ballering G, Jurado L, Falk N, Bochoeyer A, Goldsman A, Grippo M, Freilij H, Garcia Bournissen F, Chatelain E, Altcheh J. González NL, et al. Among authors: altcheh j. PLoS Negl Trop Dis. 2022 Dec 19;16(12):e0010968. doi: 10.1371/journal.pntd.0010968. eCollection 2022 Dec. PLoS Negl Trop Dis. 2022. PMID: 36534647 Free PMC article.
Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE).
Altcheh J, Sierra V, Ramirez T, Pinto Rocha JJ, Grossmann U, Huang E, Moscatelli G, Ding O. Altcheh J, et al. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0119322. doi: 10.1128/aac.01193-22. Epub 2023 Mar 28. Antimicrob Agents Chemother. 2023. PMID: 36975790 Free PMC article. Clinical Trial.
Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation.
Altcheh J, Moscatelli G, Caruso M, Moroni S, Bisio M, Miranda MR, Monla C, Vaina M, Valdez M, Moran L, Ramirez T, Patiño OL, Riarte A, Gonzalez N, Fernandes J, Alves F, Ribeiro I, Garcia-Bournissen F. Altcheh J, et al. PLoS Negl Trop Dis. 2023 May 31;17(5):e0010850. doi: 10.1371/journal.pntd.0010850. eCollection 2023 May. PLoS Negl Trop Dis. 2023. PMID: 37256863 Free PMC article.
Deep serological profiling of the Trypanosoma cruzi TSSA antigen reveals different epitopes and modes of recognition by Chagas disease patients.
Romer G, Bracco LA, Ricci AD, Balouz V, Berná L, Villar JC, Ramsey JM, Nolan MS, Torrico F, Kesper N, Altcheh J, Robello C, Buscaglia CA, Agüero F. Romer G, et al. Among authors: altcheh j. PLoS Negl Trop Dis. 2023 Aug 9;17(8):e0011542. doi: 10.1371/journal.pntd.0011542. eCollection 2023 Aug. PLoS Negl Trop Dis. 2023. PMID: 37556493 Free PMC article.
104 results